Skip to main content

Table 1 Baseline clinical and laboratory parameters

From: Immunogenicity and safety of influenza vaccination in patients with juvenile idiopathic arthritis on biological therapy using the microneutralization assay

Variables Control group
(n = 6)
JIA group
(n = 35)
Biological therapy
(n = 25)
Non biological therapy
(n = 10)
Female n (%) 4 (66.6) 23 (65.7) 17 (68) 6 (60)
Age in y (IQR) 11.6 (9.8-14.6) 10.6 (8.8-12.7) 11.4 (8.9-13.0) 11.4 (4.7-12.3)
Previous seasonal vaccination n (%) 2 (33) 22 (62.8) 18 (72) 4 (40)
Duration of JIA in y (IQR)   4.9 (2.7-8.3) 5.99 (3.0-8.6) 3.94 (2.5-4.7)
JIA category n (%)
 Persistent oligoarthritis   13 (37.1) 7 (28) 6 (60)
 Extended oligoarthritis   6 (17.1) 5 (20) 1 (10)
 Polyarthritis RF negative   6 (17.1) 4 (16) 2 (20)
 Polyarthritis RF positive   0 (0) 0 (0) 0 (0)
 Systemic onset arthritis   7 (20) 7 (28) 0 (0)
 Enthesitis related arthritis   3 (8.5) 2 (8) 1 (10)
 Psoriatic arthritis   0 0 0
 Undifferentiated arthritis   0 0 0
Treatment n (%) (a)
 Without therapy   3 (8.5) _ 3 (30)
 Systemic corticosteroids (concomitant MTX + tocilizumab)   2 (5.7) 2 (8)  
 Methotrexate monotherapy   7 (20) _ 7 (70)
 Biological monotherapy   16 (45.7) 16 (64) _
 Biological therapy + methotrexate   9 (25.7) 9 (36) _
Duration of biological therapy in years (IQR) NA NA 3.1 (1.8-4.8) NA
JADAS 71 (IQR)   1 (0-5) 3 (0-7) 2 (0.25-6.75)
IgG mg/dl (IQR)   1036 (888-1243) 1021 (880-1249) 1143 (965-1205)
Leukocytes ×109/L (IQR) 6.5 (3.7-8.2) 6.0 (5.2-7.4) 5.8 (5.0-6.9) 7.5 (5.9-9.1)
Lymphocytes ×109/L 2.3 (1.3-2.5) 2.2 (1.6-2.8) 2.2 (1.6-2.8) 2.283 (1.9-3.1)
Neutrophils ×109/L 3.4 (2.0-4.7) 3.1 (2.7-3.9) 3.1 (2.5-3.6) 3.9 (3.0-4.7)
Hemoglobin g/L (IQR) 13.3 (12.8-13.6) 13.3 (12.7-13.6) 13.3 (12.8-14.2) 13.1 (12.2-13.3)
Platelets ×109/L (IQR) 305 (289-376) 263 (234-320) 255 (227-318) 275 (251-356)
ESR mm/h (IQR) 5 (4.0-9.5) 8 (4.0-10.5) 6 (4.0-9.0) 8.5 (6.5-10.8)
  1. Values are expressed as median unless stated otherwise; IQR interquartile range, JIA juvenile idiopatic arthritis; y years; MTX methotrexate, IgG immunoglobulin G, ESR erythrocyte sedimentation rate, NA not applicable
  2. (a)Methotrexate was given at a dose of 10-15 mg/m2/week (35% received lower doses due to clinical remission). Systemic corticosteroids included oral 0.1 mg/kg/day in a patient and 10 mg/kg/dose iv in the remaining patients. Biological therapy included: tocilizumab 8 mg/kg/dose monthly or fortnightly (polyarticular or systemic JIA respectively), anakinra 2-4 mg/kg/day, etanercept 0.8 mg/kg/week and adalimumab 24 mg/kg/m2 (52% of patients received lower doses due to clinical remission). Biological therapy was administered simultaneously with the influenza vaccination